Laura Joszt, MA

Costs remain the top concern of healthcare purchasers of pharmacy benefits, but employers are also concerned with ensuring appropriate use of medication and adherence to medication, according to a new report from the Pharmacy Benefit Management Institute (PBMI).

A policy from the Trump administration to benefit patients and alleviate the high cost of prescription drugs would eliminate rebates from pharmaceutical companies to pharmacy benefit managers.

New research has identified the origins of acute myeloid leukemia, which can be detectable more than 5 years before the disease develops.

New research identified predictors of long-term survival and health-related quality of life in patients with newly diagnosed multiple myeloma.

Currently, many patients experience a more than 3-month delay until their diagnosis is confirmed.

Quizartinib has prolonged survival in patients with a rare and deadly form of acute myeloid leukemia.

Using gene editing to remove CD33, a protein targeted to treat acute myeloid leukemia with chimeric antigen receptor (CAR) T cells, from healthy stem cells could reduce toxicity experienced by CAR T-cell therapy.

From 1990 to 2016, incident cases and deaths from multiple myeloma have grown substantially.

Patients with relapsed/refractory B-cell acute lymphoblastic leukemia (ALL) who were treated with inotuzumab ozogamicin (InO) indicated better quality of life, functioning, and symptom scores compared with patients receiving standard-of-care chemotherapies.

Humana has designed a new value-based care maternity bundled payment model to improve quality, outcomes, and cost across the entire perinatal episode of care for commercial group members with low- to moderate-risk pregnancies.

There are 40 genes involved in the development of multiple myeloma, according to new research.

Although the risk of neurocognitive issues is common in survivors of childhood lymphoblastic leukemia (ALL), a new study suggests that the risk may actually begin before treatment.

Reports from The Lancet's Taskforce of Non-Communicable Diseases highlight the potential health and economic impact of taxes on soft drinks, alcohol, and tobacco.

The rivaroxaban plus aspirin combination therapy to treat patients with stable coronary or peripheral artery disease showed such benefits in the COMPASS trial that it should become the standard of care.

In this clip, Deepak Bhatt, MD, discusses the results of the COMPASS (Cardiovascular OutcoMes for People using Anticoagulation StrategieS) trial, presented at the European Society of Cardiology Congress 2017, held August 26-30 in Barcelona, Spain.

Pfizer and Allergan announce $160 billion merger, which is the second-largest in the healthcare industry's history and the largest to use a controversial tax-saving strategy.

CMS aims to provide choice and competition for consumers and improve the consumer experience.

Express Scripts removes specialty pharmacy Linden Care from its network.

Initiative does not prohibit the purchase or sale of private coverage duplicating the public plan.

Nonadherence carries significant implications for stakeholders throughout the specialty space.

Spending on brand prescription drugs increased despite a 16% decrease in the use of these drugs.

Senator Tim Kaine (D-VA) discussed Medicaid expansion, the Affordable Care Act, and politics at America's Health Insurance Plans' National Conference on Medicaid.

Medicare Part D is nearly 50% under budget with premiums almost 40% less than originally projected.

Researchers seek to increase transparency and diminish the added burdens on the workforce.